试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-19
Very Small Embryonic-like Stem Cells for Knee Osteoarthritis
编号:NCT03975101登记状态:入组前撤回企业 / 申办者:Fuda Cancer Hospital, Guangzhou
药物 / 成分:very small embryonic-like stem cell
登记的停止原因(原文):Policy changes have contributed to the failure to carry out smoothly
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-19
Very Small Embryonic-like Stem Cells for Facial Skin Antiaging
编号:NCT03976206登记状态:入组前撤回企业 / 申办者:Fuda Cancer Hospital, Guangzhou
药物 / 成分:Very small embryonic-like stem cell
登记的停止原因(原文):Policy changes have contributed to the failure to carry out smoothly
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-19
Very Small Embryonic-like Stem Cells for Ovary
编号:NCT03985462登记状态:入组前撤回企业 / 申办者:Fuda Cancer Hospital, Guangzhou
药物 / 成分:very small embryonic-like stem cell
登记的停止原因(原文):Policy changes have contributed to the failure to carry out smoothly
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-19
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
编号:NCT04388189登记状态:入组前撤回企业 / 申办者:Alto Neuroscience
药物 / 成分:Duloxetine、Bupropion
登记的停止原因(原文):No participants enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-19
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
编号:NCT04388202登记状态:入组前撤回企业 / 申办者:Alto Neuroscience
药物 / 成分:Sertraline、Escitalopram
登记的停止原因(原文):No participants enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-19
Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF
编号:NCT04592380登记状态:入组前撤回企业 / 申办者:The Medicines Company
药物 / 成分:Stage 1: Clevidipine (double-blinded)、Stage 1: Placebo (double-blinded)、Stage 2: Clevidipine (open-label)、Stage 2: Standard of Care (open-label)
登记的停止原因(原文):Product was divested to Chiesi USA, who decided to not move forward with study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-14
Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
编号:NCT00838227登记状态:入组前撤回企业 / 申办者:Manhattan Psychiatric Center
药物 / 成分:modafinil
登记的停止原因(原文):No source of funding to implement the study.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-14
Vascular Inflammation and Cholesterol Lowering Therapy
编号:NCT02941016登记状态:入组前撤回企业 / 申办者:Copenhagen University Hospital, Rigshospitalet
药物 / 成分:Evolocumab or Alirocumab
登记的停止原因(原文):Logistic reasons
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-14
Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women
编号:NCT04212065登记状态:入组前撤回企业 / 申办者:Ohio State University
药物 / 成分:buprenorphine
登记的停止原因(原文):closed due to new safety concerns of subcutaneous buprenorphine in pregnant patients
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-10-14
CSL324 in COVID-19
编号:NCT04519424登记状态:入组前撤回企业 / 申办者:CSL Behring
药物 / 成分:CSL324、Placebo
登记的停止原因(原文):Due to business reasons, not safety issues.
查看官方原始记录 ↗